Tickertape - Financial freedom begins here

Ramkrishna Forgings announced that India Rating and Research has downgraded the long term credit ratings to IND AA-; Stable from IND AA and affirmed the short term ratings at IND A1+.

Renaissance Global has allotted 8,410 equity shares under ESOS on 19 May 2026. Consequent to this allotment, the paid-up equity share capital of the Company stands increased from Rs. 21,46,50,942 comprising of 10,73,25,471 equity shares of Rs.2/- each fully paid-up to Rs. 21,46,67,762 comprising of 10,73,33,881 equity shares of Rs.2/- each fully paid-up.

Aether Industries has allotted 29,075 equity shares under ESOS on 19 May 2026. With this allotment, the paid up equity share capital has increased to 13,27,08,899 equity shares of Rs. 10 each.

STL Networks has allotted 44,996 equity shares under ESOS on 18 May 2026. With this allotment, the paid up equity share capital has increased to 48,80,76,500 equity shares of Rs 2 each.

HDFC Bank has allotted 7,96,290 equity shares to the employees of the Bank pursuant to exercise of Options/RSU's under its Employees Stock Options Scheme (ESOS). The Paid-up Share Capital of the Bank will accordingly increase from 15,39,55,35,906 equity shares of Re. 1/- each to 15,39,63,32,196 equity shares of Re.1/- each.

The board of Dhanuka Agritech at its meeting held on 19 May 2026 has approved the proposal to buyback up to 5,00,000 fully paid up equity shares at a price of Rs 1,400 per equity share for an amount not exceeding Rs 70 crore.

Dhanuka Agritech has fixed 29 May 2026 as record date for the purpose of determining the entitlement and the names of equity shareholders who are eligible to participate in the proposed Buyback Offer.

Revenue from operations fell 12.43% year-on-year to Rs 1,632.53 crore in the quarter ended 31 March 2026. Profit before tax (PBT) stood at Rs 146.44 crore, reflecting a decline of 14.71% from Rs 171.71 crore reported in Q4 FY25. On a segmental basis, revenue from yarn declined 6.27% to Rs 851.25 crore, towel revenue fell 20.15% to Rs 601.12 crore and bedsheets revenue dropped 33.18% to Rs 210.57 crore. However, revenue from paper and chemicals rose 10.59% to Rs 296.83 crore. For the full financial year FY26, the company posted a 1.95% increase in consolidated net profit to Rs 377.11 crore, while revenue declined 4.09% to Rs 6,701.05 crore compared with FY25. Net cash used in operating activities stood at Rs 760.18 crore in FY26, compared with net cash from operating activities of Rs 945 crore in the previous year. Trident is one of the largest towel manufacturers in the world, one of the world's largest agro-based paper manufacturers, and one of the largest yarn producers in India. Trident is a vertically integrated textile (yarn, bath & bed linen) and paper (wheat-straw-based) manufacturer. The counter rose 0.58% to end at Rs 24.44 on the BSE. Powered by Capital Market - Live

Union Minister of Commerce and Industry Piyush Goyal addressed the ASSOCHAM India Business Reform Summit 2026 in New Delhi today and called for deeper collaboration between industry and government to advance ease of doing business, enhance India's competitiveness and accelerate the country's journey towards Viksit Bharat 2047. The Minister said the present global situation and geopolitical uncertainties should be viewed as an opportunity for India to strengthen business processes, undertake faster reforms, build greater resilience and strengthen supply chains. He expressed confidence that the country would convert current global risks into opportunities for growth and reform. Speaking on the evolving global situation and the West Asia crisis, he noted that businesses should remain alert to both opportunities and risks without panicking. He said India had successfully overcome unpredictable challenges such as COVID-19 and emphasised the need for smarter and more efficient business practices, including reducing waste, improving productivity and adopting energy efficiency measures.Powered by Capital Market - Live

Profit before exceptional item and tax (PBT) increased 8.75% YoY to Rs 2,057.2 crore in Q4 FY26. During the quarter, the company reported an exceptional item of Rs 397.5 crore, primarily on account of a one-time expenditure related to the Mirabegron litigation settlement. EBITDA stood at Rs 2,554.4 crore in Q4 FY26, registering the growth of 20.2% compared with Rs 2,125.5 crore in Q4 FY25. EBITDA margin improved to 33.7% in Q4 FY26 as against 32.6% in Q4 FY25. The company's organic capital expenditure for the quarter stood at Rs 357.7 crore. Revenue from India formulation business jumped 14% YoY to Rs 1,752.8 crore, contributing 24% to consolidated revenue. Branded business grew faster than the market with 15% YoY growth. North America formulation business registered revenues of Rs 2,952.3 crore, down 6% YoY and accounted for 40% of consolidated revenue. In constant currency terms, the business posted revenue of $323 milion. Revenue from international markets formulation business stood at Rs 804.1 crore, up 45% YoY. The business accounted for 11% of consolidated revenues. The growth was broad-based across regions, led by robust demand in emerging markets and Europe, aided by focused execution Revenue from consumer wellness business climbed 61% YoY to Rs 1,463.3 crore. Domestic business grew by 1.7% YoY. Within the domestic business, the seasonal brands declined by 9.8%, whereas the skin & hair care brands and food & nutrition brands registered 39.7% and 9.4% YoY growth respectively. On full year basis, the company's consolidated net profit jumped 11.37% to Rs 5,040 crore in FY26 compared with Rs 4,525.5 crore in FY25. Revenue from operations increased 16.81% to Rs 27,148.4 crore in FY26 compared with Rs 23,241.5. Meanwhile, the company's board recommended a final dividend of Re 1 per equity share of face value Re 1 each for FY26, subject to shareholders' approval at the forthcoming Annual General Meeting (AGM) scheduled on Tuesday, 11 August 2026. The company has fixed 24 July 2026 as the record date for determining shareholders eligible for the dividend. Further, the board also approved a share buyback of up to 95,65,217 equity shares aggregating up to Rs 1,100 crore at a price of Rs 1,150 per share, representing a premium of 16.02% over the stock's closing price of Rs 991.20 on 18 May 2026. The record date for the buyback has been fixed as 29 May 2026. As on 15 May 2026, promoters and the promoter group held a 74.9950% stake in the company. Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.Powered by Capital Market - Live